RBM46

Across TCGA pan-cancer cohorts, RBM46 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of RBM46’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RBM46 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RBM46 is over-expressed in tumor, although a few such as COAD and THCA show the opposite, repressed pattern.

KIRC, HNSC, and COAD are the cancer types where RBM46 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RBM46 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+0.410	<.001	12	view →
HNSC	All	II,III,IV	+0.065	.004	7	view →
COAD	Male	All	−0.021	<.001	5	view →
THCA	Male	All	−0.697	<.001	4	view →
LUAD	All	All	+0.095	.007	3	view →
BRCA	All	III,IV	−0.106	<.001	2	view →
KIRP	All	All	+0.099	.024	1	view →
LIHC	Female	II,III,IV	−0.035	.009	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

RBM46–KIRC

Open the KIRC breakdown →